Bli medlem
Bli medlem

Du är här


Moberg Pharma: Moberg Pharma receives bondholders' approval for increased flexibility in acquisition financing

STOCKHOLM, November 28th, 2016 - Moberg Pharma AB (OMX: MOB) has
obtained a waiver from its bondholders to increase flexibility in
acquisition financing. The waiver provides better possibility to
optimize financing of acquisitions of profitable assets.

Moberg Pharma's outstanding senior unsecured floating rate bonds are
due 2021, and encompass maximum SEK 600 million with a current
outstanding amount of SEK 385 million (the "Bonds"). On November 8th,
2016 Moberg Pharma summoned a bondholders' meeting, by way of a
written procedure, to obtain a waiver from the holders of the Bonds
(the "Waiver Solicitation and the "Waiver"). The purpose of the
Waiver Solicitation is to enable the company to fully utilize its
outstanding bond facility for accretive acquisition opportunities
currently under evaluation. The focus remains on acquisitions of
profitable brands which can be easily integrated in Moberg Pharma's
existing infrastructure.

The time for replies expired on November 25th, 2016 and a sufficient
number of votes have been obtained to form a quorum. The Waiver
Solicitation has obtained a majority exceeding 99 percent
(representing approximately 74 percent of the total number of
outstanding Bonds) and the Waiver has thereby been granted.

The option to utilize the Waiver, which Waiver enables the company to
at one occasion in conjunction with an acquisition increase its ratio
of net debt to EBITDA to 4.5, becomes effective immediately after
November 25th, 2016 and is valid up to the end of 2017. Upon a
utilization of the Waiver, Moberg Pharma will pay a consent fee to
the holders of the Bonds of 0.50 percent of the outstanding nominal
amount of the Bonds at the time of the Waiver-utilization.

"We appreciate the increased flexibility which our bondholders have
granted the company and hence enhanced our possibilities to optimally
finance accretive acquisitions", commented Peter Wolpert, Moberg
Pharma's CEO.

For further information regarding the Waiver, please be referred to
the company's press release from November 8th, 2016.

Moberg Pharma appointed Carnegie Investment Bank as financial adviser
and Gernandt & Danielsson Advokatbyrå as legal adviser in conjunction
with the Waiver Solicitation.

About this information
This information is information that Moberg Pharma AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the
contact person set out above, at 08:30 a.m. CET on November 28th,

For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail:

Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical
company with OTC sales operations in the U.S. and a distributor
network in more than 40 countries. The company's portfolio includes
the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Domeboro®,
Fiber Choice® and PediaCare®. Kerasal Nail® (Emtrix® or Nalox™ in
certain markets) is a leading OTC treatment of nail disorders in the
U.S., Canada as well as in several markets in EU and Southeast Asia.
The company is growing organically as well as through acquisitions.
Internal development programs focuses on innovative drug delivery of
proven compounds and include two clinical stage assets, MOB-015
(onychomycosis) and BUPI (pain management in oral mucositis). Moberg
Pharma has offices in Stockholm and New Jersey and the company's
shares are listed on the Small Cap list of the NASDAQ OMX Nordic
Exchange Stockholm (MOB.ST).


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.